bioAffinity Technologies, Inc. - SIC # 8010 -

Ticker Exchange SIC # Website Latest Ticker
BIAF Nasdaq 8010 www.bioaffinitytech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for bioAffinity Technologies, Inc.

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board - Feb 9th, 2026 6:00 am
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation - Jan 7th, 2026 6:00 am
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Dec 3rd, 2025 6:00 am
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss - Nov 19th, 2025 9:33 am
bioAffinity Technologies Reports Third Quarter 2025 Financial Results - Nov 14th, 2025 6:00 am
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume - Nov 5th, 2025 6:00 am
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases - Oct 28th, 2025 6:00 am
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 - Oct 20th, 2025 6:00 am
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer - Oct 16th, 2025 6:00 am
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Oct 15th, 2025 6:00 am
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Oct 9th, 2025 12:00 pm
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Oct 9th, 2025 11:00 am
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Oct 8th, 2025 2:15 pm
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Oct 8th, 2025 1:45 pm
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 - Oct 7th, 2025 6:00 am
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m - Sep 30th, 2025 10:30 am
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering - Sep 30th, 2025 10:15 am
WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m - Sep 29th, 2025 3:59 pm
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering - Sep 29th, 2025 1:51 pm
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung - Sep 26th, 2025 6:00 am